Trastuzumab (Herceptin)

References

Citations

1. Piccart-Gebhart MJ, et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, 353(16): 1659–1672.

2. Shapiro CL (2003). Metastatic breast cancer. In B Furie et al., eds., Clinical Hematology and Oncology, pp. 750–762. Philadelphia: Churchill Livingstone.

3. Romond EH, et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353(16): 1673–1684.

4. Smith I, et al. (2007). Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet, 369(9555): 29–36.

Author:	Kathe Gallagher, MSW	Last Updated: August 31, 2007
Medical Review:	Joy Melnikow, MD, MPH - Family Medicine Douglas A. Stewart, MD - Medical Oncology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.